Last reviewed · How we verify
PBT2
At a glance
| Generic name | PBT2 |
|---|---|
| Sponsor | Prana Biotechnology Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- DENTOFACIAL-PBT Stage 2 - Feasibility Study
- Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease (PHASE2)
- Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine (PHASE1)
- Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2 (PHASE1)
- Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2 (PHASE1)
- Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PBT2 CI brief — competitive landscape report
- PBT2 updates RSS · CI watch RSS
- Prana Biotechnology Limited portfolio CI